Date: 2016-03-18
Type of information: Distribution agreement
Compound: Akynzeo® (oral fixed-dose combination capsule of netupitant 300 mg + palonosetron 0.50 mg (NEPA)) Aloxi® (palonosetron HCl)
Company: Eisai (Japan) Helsinn (Switzerland)
Therapeutic area: Digestive diseases - Gastrointestinal diseases - Inflammatory diseases
Type agreement: distribution
Action mechanism: antiemetic agent. NEPA is an investigational single-day, fixed-dose combination of a selective NK1 receptor antagonist, netupitant, and a 5-HT3 receptor antagonist, palonosetron, designed to target two critical pathways thought to be associated with chemotherapy-induced nausea and vomiting (CINV).
Disease: prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) following both highly and moderately emetogenic chemotherapy
Details: * On March 18, 2016, Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, and Eisai Inc., the U.S. pharmaceutical subsidiary of the research-based human healthcare company Eisai Co., Ltd , announced today a revised agreement for their chemotherapy-induced nausea and vomiting (CINV) franchise. Under the new arrangement, Helsinn Therapeutics Inc., the U.S. affiliate of Helsinn, will obtain exclusive rights to promote and sell Akynzeo® (netupitant/palonosetron), its oral fixed dose combination product for the prevention of CINV. Akynzeo® had previously been co-promoted in the U.S. by both Helsinn and Eisai. As part of the revised agreement, Eisai and Helsinn will continue to co-promote Aloxi® (palonosetron HCl) injection in the U.S. for CINV. This revised arrangement will enable Eisai to focus on Aloxi® and its oncology franchise.
Financial terms:
Latest news:
